Kroe-Barrett R - Search Results

1

Optimizing NBE PK/PD assays using the Gyrolab Affinity Software; conveniently within the bioanalyst's existing workflow.

Myzithras M, Bigwarfe T, Waltz E, Li H, Ahlberg J, Rybina I, Low S, Kenny CH, Miglietta J, Kroe-Barrett R. Myzithras M, et al. Bioanalysis. 2018 Mar 1;10(6):397-406. doi: 10.4155/bio-2017-0251. Epub 2018 Feb 16. Bioanalysis. 2018. PMID: 29451404

2

Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn.

Yang D, Giragossian C, Castellano S, Lasaro M, Xiao H, Saraf H, Hess Kenny C, Rybina I, Huang ZF, Ahlberg J, Bigwarfe T, Myzithras M, Waltz E, Roberts S, Kroe-Barrett R, Singh S. Yang D, et al. MAbs. 2017 Oct;9(7):1105-1117. doi: 10.1080/19420862.2017.1359455. Epub 2017 Aug 8. MAbs. 2017. PMID: 28786732 Free PMC article.

3

Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5).

Ahlberg J, Giragossian C, Li H, Myzithras M, Raymond E, Caviness G, Grimaldi C, Brown SE, Perez R, Yang D, Kroe-Barrett R, Joseph D, Pamulapati C, Coble K, Ruus P, Woska JR, Ganesan R, Hansel S, Mbow ML. Ahlberg J, et al. Among authors: kroe barrett r. MAbs. 2019 Jul;11(5):956-964. doi: 10.1080/19420862.2019.1615345. Epub 2019 Jun 4. MAbs. 2019. PMID: 31068073 Free PMC article.

4

Non-neutralizing antibodies increase endogenous circulating Ang1 levels.

Zheng C, Toth J, Bigwarfe T, MacDougall M, Jerath K, Bovat K, Smith J, Sun P, Hayes D, Fryer R, Singh S, Kroe-Barrett R. Zheng C, et al. MAbs. 2018 Nov-Dec;10(8):1260-1268. doi: 10.1080/19420862.2018.1521130. Epub 2018 Nov 7. MAbs. 2018. PMID: 30199300 Free PMC article.

5

Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody.

Singh S, Kroe-Barrett RR, Canada KA, Zhu X, Sepulveda E, Wu H, He Y, Raymond EL, Ahlberg J, Frego LE, Amodeo LM, Catron KM, Presky DH, Hanke JH. Singh S, et al. MAbs. 2015;7(4):778-91. doi: 10.1080/19420862.2015.1032491. Epub 2015 Apr 23. MAbs. 2015. PMID: 25905918 Free PMC article.

6

Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies.

Ganesan R, Raymond EL, Mennerich D, Woska JR Jr, Caviness G, Grimaldi C, Ahlberg J, Perez R, Roberts S, Yang D, Jerath K, Truncali K, Frego L, Sepulveda E, Gupta P, Brown SE, Howell MD, Canada KA, Kroe-Barrett R, Fine JS, Singh S, Mbow ML. Ganesan R, et al. MAbs. 2017 Oct;9(7):1143-1154. doi: 10.1080/19420862.2017.1353853. Epub 2017 Jul 20. MAbs. 2017. PMID: 28726542 Free PMC article.

7

VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis.

Low S, Wu H, Jerath K, Tibolla A, Fogal B, Conrad R, MacDougall M, Kerr S, Berger V, Dave R, Villalona J, Pantages L, Ahlberg J, Li H, Van Hoorick D, Ververken C, Broadwater J, Waterman A, Singh S, Kroe-Barrett R. Low S, et al. Among authors: kroe barrett r. MAbs. 2020 Jan-Dec;12(1):1709322. doi: 10.1080/19420862.2019.1709322. MAbs. 2020. PMID: 31924119 Free PMC article.

8

Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodies.

Venkataramani S, Low S, Weigle B, Dutcher D, Jerath K, Menzenski M, Frego L, Truncali K, Gupta P, Kroe-Barrett R, Ganesan R, Singh S, Erb KJ. Venkataramani S, et al. Biochem Biophys Res Commun. 2018 Sep 26;504(1):19-24. doi: 10.1016/j.bbrc.2018.08.064. Epub 2018 Aug 17. Biochem Biophys Res Commun. 2018. PMID: 30126632

9

Sema3A Antibody BI-X Prevents Cell Permeability and Cytoskeletal Collapse in HRMECs and Increases Tip Cell Density in Mouse Oxygen-Induced Retinopathy.

Zippel N, Kenny CH, Wu H, Garneau M, Kroe-Barrett R, Gupta P, Low S, Bakker RA, Thomas L. Zippel N, et al. Among authors: kroe barrett r. Transl Vis Sci Technol. 2022 Jun 1;11(6):17. doi: 10.1167/tvst.11.6.17. Transl Vis Sci Technol. 2022. PMID: 35727188 Free PMC article.

10

An optimally designed anti-human CD40 antibody with potent B cell suppression for the treatment of autoimmune diseases.

Wu HH, Ralph KL, Sepuldeva E, Hansen G, Li H, Huang ZF, Liu D, Dziegelewski M, Ahlberg J, Frego L, Fogal S, van Tongeren S, Grimaldi C, Litzenberger T, Presky D, Singh S, Brodeur S, Kroe-Barrett R. Wu HH, et al. Among authors: kroe barrett r. Int J Pharm. 2021 Nov 20;609:121162. doi: 10.1016/j.ijpharm.2021.121162. Epub 2021 Oct 6. Int J Pharm. 2021. PMID: 34624444

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters